Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential
Alessandro Rizzo, Antonio Cusmai, Silvana Acquafredda, L. Rinaldi, Gennaro Palmiotti
Abstract
KEYWORDS: Breast cancertriple negative breast cancercombinationsantibody drug conjugatesacituzumab govitecanladiratuzumab vedotin
Topics & Concepts
Triple-negative breast cancerKey (lock)CancerMedicineOncologyInternal medicineCancer researchBiologyBreast cancerEcologyHER2/EGFR in Cancer ResearchCancer Immunotherapy and BiomarkersCAR-T cell therapy research